ClinicalTrials.gg

Program

Influenza virus split vaccine (0.7mL/vial)

Its studies are mostly in Influenza, Human, led by Sinopharm.

Furthest: phase 2, since Dec 25, 20252 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinopharm22 open or runningphase 2since Dec 25, 2025Dec 11, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 11, 2025First study: phase 1 study in Influenza, HumanFirst studyNCT07302256 · 120 planned · China
  2. Dec 25, 2025Phase 2 study in Influenza, HumanPhase 2 reachedNCT07327398 · 1,200 planned · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Influenza virus split vaccine (0.7mL/vial)”name, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07327398Influenza, Human · China2Not yet recruitingSep 30, 20261,200
NCT07302256Influenza, Human · China1RecruitingAug 31, 2026120

How it is read

Names in the registry

  • “Influenza virus split vaccine (0.7mL/vial)”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.